SSKN · As filed with the SEC

STRATA Skin Sciences cash flow statement, by quarter

The statement as STRATA Skin Sciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Statements of Cash Flows · USD thousands

USD thousands	Q4 2025^† 3 months ended Dec 31, 2025	Q3 2025^† 3 months ended Sep 30, 2025	Q2 2025^† 3 months ended Jun 30, 2025	Q1 2025 3 months ended Mar 31, 2025	Q4 2024^† 3 months ended Dec 31, 2024	Q3 2024^† 3 months ended Sep 30, 2024	Q2 2024^† 3 months ended Jun 30, 2024	Q1 2024 3 months ended Mar 31, 2024
Cash flows from operating activities:
Net loss	58^†	(1,398)^†	(2,489)^†	(2,432)	(4,555)^†	(2,122)^†	(99)^†	(3,368)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	821^†	864^†	1,218^†	1,220	1,230^†	1,239^†	1,250^†	1,249
Amortization of operating lease right-of-use assets	85^†	87^†	87^†	85	84^†	81^†	79^†	95
Amortization of deferred financing costs and debt discount	39^†	40^†	39^†	39	39^†	39^†	39^†	31
Provision for credit losses	13^†	(50)^†	56^†	110	(142)^†	(70)^†	(54)^†	84
Stock-based compensation expense	174^†	212^†	128^†	129	126^†	26^†	163^†	112
Loss on disposal of property and equipment	9^†	20^†	29^†	34	11^†	19^†	6^†	13
Inventory write-off	0^†	0^†	0^†	0	21^†	0^†	0^†	141
Changes in operating assets and liabilities:
Accounts receivable	(630)^†	568^†	929^†	136	(668)^†	(394)^†	(295)^†	726
Inventories	342^†	282^†	(535)^†	(377)	558^†	8^†	160^†	(154)
Prepaid expenses and other assets	(119)^†	(84)^†	(186)^†	137	(204)^†	134^†	(88)^†	(31)
Accounts payable	(124)^†	9^†	103^†	362	684^†	(1,172)^†	(727)^†	261
Accrued expenses and other liabilities	(48)^†	1^†	(1,370)^†	169	148^†	1,886^†	347^†	(57)
Deferred revenues	(325)^†	150^†	133^†	(81)	(227)^†	96^†	(120)^†	194
Operating lease liabilities	(83)^†	(81)^†	(83)^†	(81)	(77)^†	(72)^†	(70)^†	(100)
Net cash (used in) provided by operating activities	(239)^†	(64)^†	(1,941)^†	(550)	703^†	(302)^†	591^†	(804)
Cash flows from investing activities:
Purchase of property and equipment	(312)^†	(1,018)^†	61^†	(199)	(504)^†	(62)^†	(345)^†	(725)
Net cash used in investing activities	(312)^†	(1,018)^†	61^†	(199)	(504)^†	(62)^†	(345)^†	(725)
Cash flows from financing activities:
Payment of contingent consideration	0^†	0^†	0^†	0	0^†	0^†	0^†	(18)
Sale of common stock, net of offering costs	1,387^†	—	—	—	0^†	—	—	—
Net cash provided by financing activities	1,387^†	2,192^†	0^†	0	0^†	1,943^†	0^†	(18)
Net (decrease) increase in cash, cash equivalents and restricted cash	836^†	1,110^†	(1,880)^†	(749)	199^†	1,579^†	246^†	(1,547)
Cash, cash equivalents and restricted cash at beginning of year	7,076	5,966	7,846	8,595	8,396	6,817	6,571	8,118
Cash, cash equivalents and restricted cash at end of year	7,912	7,076	5,966	7,846	8,595	8,396	6,817	6,571
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	445^†	459^†	457^†	450	483^†	500^†	510^†	480
Supplemental schedule of non-cash operating, investing and financing activities:
Transfer of property and equipment to inventories	98^†	104^†	42^†	36	81^†	60^†	157^†	9
Accrued exit fee recorded as debt discount	0^†	—	—	—	0^†	150^†	—	—
Accrued payment of contingent consideration	0^†	(47)^†	26^†	21	0^†	35^†	3^†	6
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	0^†	0^†	0^†	0	0^†	0^†	0^†	977

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.